Literature DB >> 23962405

Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study.

Bernardo Dell'Osso1, Cristina Dobrea1, Chiara Arici1, Beatrice Benatti1, Roberta Ferrucci2, Maurizio Vergari2, Alberto Priori2, A Carlo Altamura1.   

Abstract

OBJECTIVES: Transcranial direct current stimulation (tDCS) is a non-invasive neurostimulation technique that has received increasing interest in the area of mood disorders over the last several years. While acute, double-blind, sham-controlled studies have already reported positive findings in terms of efficacy and safety for tDCS, follow-up data are lacking. This need prompted the present follow-up study, which assesses post-acute effects of tDCS (no maintenance stimulation was performed), in the mid-term, in a sample of major depressives.
METHODS: After completing an acute, open trial of tDCS, 23 outpatients with either major depressive disorder or bipolar disorder entered a naturalistic follow-up (T1) with clinical evaluations at one week (T2), 1 month (T3), and 3 months (T4). A quantitative analysis of Hamilton Depression Rating Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), and Young Mania Rating Scale (YMRS) total scores, through repeated measures analysis of variance (ANOVA) (T1-T4) and paired t-test for comparing specific time points (T1-T2, T2-T3, and T3-T4), was performed. In addition, a qualitative analysis on the basis of treatment response and remission (HAM-D) was performed.
RESULTS: Even though a progressive reduction of follow-up completers was observed from T2 to T4 (95.6% at T2, 65.2% at T3, and 47.8% at T4), the antidepressant effects of acute tDCS persisted over 3 months in almost half of the sample. Of note, no post-acute side effects emerged during the follow-up observation. The most frequent causes of drop-out from this study included major modifications in therapeutic regimen (30%) and poor adherence to follow-up visits (17%).
CONCLUSIONS: In this mid-term, open, follow-up study, tDCS showed mixed results. Further controlled studies are urgently needed to assess its effects beyond the acute phase.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23962405     DOI: 10.1017/S1092852913000497

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  5 in total

1.  Transcranial Direct Current Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review.

Authors:  Sarah M Szymkowicz; Molly E McLaren; Uma Suryadevara; Adam J Woods
Journal:  Psychiatr Ann       Date:  2016-11-08

Review 2.  tDCS for the treatment of depression: a comprehensive review.

Authors:  Ulrich Palm; Alkomiet Hasan; Wolfgang Strube; Frank Padberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-02-03       Impact factor: 5.270

3.  The morphological and molecular changes of brain cells exposed to direct current electric field stimulation.

Authors:  Simon J Pelletier; Marie Lagacé; Isabelle St-Amour; Dany Arsenault; Giulia Cisbani; Audrey Chabrat; Shirley Fecteau; Martin Lévesque; Francesca Cicchetti
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-07       Impact factor: 5.176

4.  The Role of Transcranial Direct Current Stimulation (tDCS) in Tourette Syndrome: A Review and Preliminary Findings.

Authors:  Valsamma Eapen; Richard Baker; Amelia Walter; Veena Raghupathy; Jordan J Wehrman; Paul F Sowman
Journal:  Brain Sci       Date:  2017-12-08

5.  Cost-utility analysis of transcranial direct current stimulation (tDCS) in non-treatment-resistant depression: the DISCO randomised controlled study protocol.

Authors:  Anne Sauvaget; Lydie Lagalice; Solène Schirr-Bonnans; Christelle Volteau; Morgane Péré; Cécile Dert; Annabelle Rivalland; Fabienne Tessier; Adeline Lepage; Agathe Tostivint; Thibault Deschamps; Véronique Thomas-Ollivier; Alison Robin; Noémie Pineau; Clémence Cabelguen; Nicolas Bukowski; Marie Guitteny; Auxane Beslot; Luc Simons; Hugopsy Network; Jean-Marie Vanelle; Giordano D'Urso; Samuel Bulteau; Valéry-Pierre Riche
Journal:  BMJ Open       Date:  2020-01-13       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.